[go: up one dir, main page]

AR063621A1 - Matriz polimerica insoluble en agua para la administracion de farmacos - Google Patents

Matriz polimerica insoluble en agua para la administracion de farmacos

Info

Publication number
AR063621A1
AR063621A1 ARP070104980A ARP070104980A AR063621A1 AR 063621 A1 AR063621 A1 AR 063621A1 AR P070104980 A ARP070104980 A AR P070104980A AR P070104980 A ARP070104980 A AR P070104980A AR 063621 A1 AR063621 A1 AR 063621A1
Authority
AR
Argentina
Prior art keywords
water insoluble
pharmacos
administration
polymeric matrix
polymer matrix
Prior art date
Application number
ARP070104980A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of AR063621A1 publication Critical patent/AR063621A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Composición farmacéutica que comprende (a) una matriz polimérica insoluble en agua bioerosionable que comprende un polímero poliéster, donde la matriz polimérica tiene un punto de fusión de menos de 60°C y (b) un agente activo disperso en la matriz polimérica, donde la composición se formula para liberar en forma controlable el agente activo durante un período de tiempo predeterminado a un sitio blanco. Métodos de tratamiento de una enfermedad o afección con las composiciones descriptas.
ARP070104980A 2006-11-09 2007-11-08 Matriz polimerica insoluble en agua para la administracion de farmacos AR063621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85800406P 2006-11-09 2006-11-09

Publications (1)

Publication Number Publication Date
AR063621A1 true AR063621A1 (es) 2009-02-04

Family

ID=39468600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104980A AR063621A1 (es) 2006-11-09 2007-11-08 Matriz polimerica insoluble en agua para la administracion de farmacos

Country Status (15)

Country Link
US (1) US8632809B2 (es)
EP (2) EP2409687B1 (es)
JP (2) JP5411703B2 (es)
KR (2) KR20090082447A (es)
CN (1) CN101553206B (es)
AR (1) AR063621A1 (es)
AU (1) AU2007325409B2 (es)
BR (1) BRPI0718696A2 (es)
CA (1) CA2668814A1 (es)
ES (2) ES2421206T3 (es)
MX (1) MX2009004856A (es)
PL (1) PL2091514T3 (es)
TW (1) TWI409081B (es)
WO (1) WO2008067127A2 (es)
ZA (1) ZA200902587B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
EP2192907B1 (en) * 2007-08-16 2018-04-18 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic applications
US20100226962A1 (en) * 2009-03-03 2010-09-09 Rodstrom Theron R Peri-corneal drug delivery device
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
US8211450B2 (en) * 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2658529A4 (en) * 2010-12-29 2014-10-01 Therapeutics Llc I OKULAR ACTIVE COMPOSITION SYSTEM
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
RU2598627C2 (ru) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
EP2830629A4 (en) * 2012-03-28 2016-01-20 Icahn School Of Medicine Mount Sinai COMPOSITIONS AND METHOD FOR THE REACTIVATION OF LATENT IMMUNE FIZIENZVIRUS
US20140107025A1 (en) * 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166498A1 (en) 2012-05-04 2013-11-07 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP2015086222A (ja) * 2013-09-26 2015-05-07 参天製薬株式会社 安定化された２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物
US20160199495A1 (en) 2014-01-13 2016-07-14 Alexander G. Gorkovenko Polymer Compositions in Biomedical Applications
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
PE20170937A1 (es) * 2014-09-19 2017-07-13 Glaxosmithkline Ip Dev Ltd Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112017012706A2 (pt) 2014-12-15 2018-03-13 The Johns Hopkins University formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares
KR20170106460A (ko) 2015-01-27 2017-09-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN114469872A (zh) 2015-11-12 2022-05-13 灰色视觉公司 用于治疗的聚集性微粒
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
US11389510B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
JP7189133B2 (ja) 2016-09-29 2022-12-13 アセンディス ファーマ グロース ディスオーダーズ エー／エス 徐放ｃｎｐ作動薬を用いた併用療法
US10603274B2 (en) * 2016-09-30 2020-03-31 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
EP3518897B1 (en) * 2016-09-30 2022-02-09 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
PL3985002T3 (pl) 2017-03-01 2025-09-15 Achillion Pharmaceuticals, Inc. Arylowe, heteroarylowe i heterocykliczne związki farmaceutyczne do leczenia zaburzeń medycznych
SI3592393T1 (sl) 2017-03-10 2022-04-29 Quiapeg Pharmaceuticals Ab Sprostljivi konjugati
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
JP2020519585A (ja) 2017-05-10 2020-07-02 グレイバグ ビジョン インコーポレイテッド 医学療法のための延長放出マイクロ粒子及びその懸濁液
AU2019245436B2 (en) * 2018-03-29 2024-12-12 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
CN111358750B (zh) * 2018-12-25 2023-03-07 沈阳兴齐眼药股份有限公司 一种眼用药物组合物及其医药用途
KR20250171463A (ko) 2019-02-11 2025-12-08 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3949750A (en) * 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4509949A (en) 1983-06-13 1985-04-09 The B. F. Goodrich Company Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
GB8401206D0 (en) 1984-01-17 1984-02-22 Allied Colloids Ltd Polymers and aqueous solutions
GB8414950D0 (en) 1984-06-12 1984-07-18 Allied Colloids Ltd Cationic polyelectrolytes
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
GB8622797D0 (en) 1986-09-22 1986-10-29 Allied Colloids Ltd Polymeric particles
CA1329283C (en) 1986-10-01 1994-05-03 David Farrar Water soluble polymeric compositions
US4957998A (en) * 1988-08-22 1990-09-18 Pharmaceutical Delivery Systems, Inc. Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
GB8909095D0 (en) * 1989-04-21 1989-06-07 Allied Colloids Ltd Thickened aqueous compositions
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US5013821A (en) * 1989-06-15 1991-05-07 Pharmaceutical Delivery Systems, Inc. Ortho and thio-ortho ester polymer
KR920702383A (ko) * 1989-08-28 1992-09-03 원본미기재 치료제의 방출을 조절하는데 유용한 생부식성 중합체
US5030457A (en) * 1989-08-28 1991-07-09 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5171270A (en) * 1990-03-29 1992-12-15 Herrick Robert S Canalicular implant having a collapsible flared section and method
JPH04364839A (ja) 1991-06-12 1992-12-17 Asahi Chem Ind Co Ltd 涙道閉鎖用ロッド
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5283063A (en) * 1992-01-31 1994-02-01 Eagle Vision Punctum plug method and apparatus
EP0556818A1 (en) 1992-02-19 1993-08-25 Sagami Chemical Research Center Polyester type polyfunctional macromonomer, gel and drug release controlling material responsive to changes in temperature
JPH0616799A (ja) * 1992-02-19 1994-01-25 Sagami Chem Res Center ポリエステル系多官能性マクロモノマー、ゲルおよび温度変化に応答する薬物放出制御材料
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
MY113268A (en) * 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
ATE502664T1 (de) 1993-07-19 2011-04-15 Angiotech Pharm Inc Herstellungsmethode eines stents mit anti- angiogener zusammensetzung
US5399666A (en) 1994-04-21 1995-03-21 E. I. Du Pont De Nemours And Company Easily degradable star-block copolymers
US5723005A (en) * 1995-06-07 1998-03-03 Herrick Family Limited Partnership Punctum plug having a collapsible flared section and method
JPH0920651A (ja) 1995-07-03 1997-01-21 Koken Co Ltd 注入可能な涙小管閉鎖剤
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
JP4225570B2 (ja) * 1996-03-05 2009-02-18 ロベール・ガーニー 緩衝化されたオルトエステルポリマーを含有する医薬組成物
US5962006A (en) * 1997-06-17 1999-10-05 Atrix Laboratories, Inc. Polymer formulation for prevention of surgical adhesions
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004753A (en) * 1997-12-01 1999-12-21 Incyte Pharmaceuticals, Inc. Human S1-5 ECMP-like protein
US6048522A (en) * 1997-12-10 2000-04-11 Isp Investments Inc. Controlled-release, drug-delivery composition
US5939453A (en) * 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
ES2231306T3 (es) 2000-08-04 2005-05-16 Medennium, Inc. Tapon ocular para implantar en el punto lagrimal y el canaliculo.
EP1339438B1 (en) * 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US20040068078A1 (en) * 2001-12-12 2004-04-08 Milbocker Michael T. In situ polymerizing medical compositions
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AU2003275263A1 (en) * 2002-09-26 2004-04-19 Angiotech International Ag Perivascular wraps
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー，インコーポレイテッド． 細胞スケジュール依存性抗癌剤のための処方
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
CA2573668A1 (en) 2004-07-12 2006-02-16 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
US20080038317A1 (en) 2004-09-10 2008-02-14 Chin-Ming Chang Therapeutic Lacrimal Canalicular Inserts And Related Methods
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
BRPI0709663A2 (pt) 2006-03-31 2011-07-26 Qlt Plug Delivery Inc mÉtodos de liberaÇço de drogas, estruturas e composiÇÕes para um sistema nasolacrimal
CN101528744A (zh) 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix

Also Published As

Publication number Publication date
ES2477993T3 (es) 2014-07-18
JP2010509361A (ja) 2010-03-25
TWI409081B (zh) 2013-09-21
AU2007325409A1 (en) 2008-06-05
PL2091514T3 (pl) 2014-03-31
JP2013129679A (ja) 2013-07-04
KR20090082447A (ko) 2009-07-30
ES2421206T3 (es) 2013-08-29
CA2668814A1 (en) 2008-06-05
JP5411703B2 (ja) 2014-02-12
BRPI0718696A2 (pt) 2013-12-31
ZA200902587B (en) 2010-06-30
TW200826963A (en) 2008-07-01
CN101553206A (zh) 2009-10-07
US8632809B2 (en) 2014-01-21
EP2091514A2 (en) 2009-08-26
CN101553206B (zh) 2012-11-21
KR20140032505A (ko) 2014-03-14
EP2091514B1 (en) 2013-06-05
EP2409687B1 (en) 2014-06-11
AU2007325409B2 (en) 2013-03-28
HK1132173A1 (en) 2010-02-19
US20080113027A1 (en) 2008-05-15
EP2409687A1 (en) 2012-01-25
WO2008067127A2 (en) 2008-06-05
MX2009004856A (es) 2009-06-05
WO2008067127A3 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
AR063621A1 (es) Matriz polimerica insoluble en agua para la administracion de farmacos
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
AR063620A1 (es) Implante punctal que contiene una matriz polimerica insoluble en agua
CR10349A (es) Tabletas de paracetamol de liberacion rapida
AR048773A1 (es) Sistema de administracion de droga (por ejemplo,dexametasona) para tratar una condicion ocular, implante bio-erosionable de liberacion prolongada comprendido en el anterior y uso de este ultimo para la fabricacion de dicho sistema de administracion de droga
AR056554A1 (es) Formulacion de farmaco de molecula pequena de liberacion sostenida
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
BRPI0412211A (pt) composições de liberação controlada
MY161930A (en) Antipsychotic injectable depot composition
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX2009004439A (es) Composicion de ibuprofeno.
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
AR047552A1 (es) Sistemas de suministro de farmacos de liberacion sostenida biodegradables
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
CL2008001509A1 (es) Composicion farmaceutica de liberacion prolongada que comprende micro-particulas con una matriz que comprende un polimero polilactido-co-glicolido lineal y uno ramificado y pamoato de pasireotida; proceso de elaboracion; micro-particulas; kit; uso para tratar una enfermedad asociada con un exceso de secrecion de gh y/o igf-1.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
ATE476997T1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
ECSP17081071A (es) Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos
CL2008002758A1 (es) Composicion que comprende al menos un principio activo laxante y al menos un principio activo antiespumante; uso para el tratamiento del estrenimiento.
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината

Legal Events

Date Code Title Description
FA Abandonment or withdrawal